Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment

Joint Bone Spine. 2014 Dec;81(6):549-50. doi: 10.1016/j.jbspin.2014.04.013. Epub 2014 Jun 21.

Authors

Johanna Benhamou¹, Deborah Gensburger², Roland Chapurlat²

Affiliations

¹ INSERM UMR 1033, department of rheumatology, Université de Lyon, Hospices Civils de Lyon, France. Electronic address: johanna.be@hotmail.fr.
² INSERM UMR 1033, department of rheumatology, Université de Lyon, Hospices Civils de Lyon, France.

PMID: 24962974
DOI: 10.1016/j.jbspin.2014.04.013

No abstract available

Keywords: Bisphosphonate; Denosumab; Fibrous dysplasia of bone; RANKL.

Publication types

Case Reports
Letter

MeSH terms

Analgesics / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Biomarkers / blood
Collagen Type I / blood
Denosumab
Fibrous Dysplasia of Bone / blood
Fibrous Dysplasia of Bone / complications*
Humans
Male
Middle Aged
Pain / drug therapy*
Peptides / blood
RANK Ligand / antagonists & inhibitors
Treatment Failure

Substances

Analgesics
Antibodies, Monoclonal, Humanized
Biomarkers
Collagen Type I
Peptides
RANK Ligand
collagen type I trimeric cross-linked peptide
Denosumab